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Clinical benefit has been demonstrated in patients with head and neck tumours receiving an anti-epidermal growth factor receptor
(EGFR) agent in combination with radiotherapy (RT). Recent preclinical and clinical studies suggest beneficial effects from combining
anti-angiogenic drugs with RT. To investigate the effect of combining these approaches, we evaluated in vivo the anti-tumour efficacy
of the anti-angiogenic compound bevacizumab, a highly specific monoclonal antibody directed against the vascular endothelial growth
factor (VEGF), erlotinib, an EGFR tyrosine kinase inhibitor, and irradiation given alone and in combination. Investigations were
performed using a VEGF-secreting human head and neck tumour cell line, CAL33, with a high EGFR content, injected as orthotopic
xenografts into the mouth floor of nude mice. Three days after tumour cell injection, bevacizumab (5mgkg
 1, 5 days a week, i.p.),
erlotinib (100mgkg
 1, 5 days a week, orally) and irradiation (6Gy, 3 days a week) were administered alone and in combination for
10 days. As compared with the control, concomitant administration of drugs produced a marked and significant supra-additive
decrease in tumour mass; the addition of irradiation almost completely abolished tumour growth. The drug association markedly
reduced the number of metastatic nodes and the triple combination significantly reduced the total number of pathologically positive
lymph nodes as compared with controls. The RT-induced proliferation, reflected by Ki67 labelling, was reduced to control level with
the triple combination. Radiotherapy induced a strong and very significant increase in tumour angiogenesis, which was no longer
observed when combined with erlotinib and bevacizumab. The efficacy of the combination of bevacizumabþerlotinib and RT may
be of clinical importance in the management of head and neck cancer patients.
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Agents that target epidermal growth factor receptor (EGFR)
potentially exert anti-tumour effects by inhibiting tumour cell
proliferation and survival, as well as reducing the secretion of
proangiogenic growth factors such as vascular endothelial growth
factor (VEGF) and fibroblast growth factor that stimulate tumour
neoangiogenesis (Perrotte et al, 1999; Woodburn, 1999; Ciardiello
et al, 2001). It has been reported that EGFR targeting in tumours
may also modulate the migration and formation of tube-like
structures of vascular endothelial cells (Hirata et al, 2002). More
recently, we have shown the presence of a gefitinib-sensitive
functional EGFR pathway in an immortalised microvascular
endothelial cell line of human origin (Bozec et al, 2005). Thus, in
addition to direct effects on tumour cells, EGFR-targeting drugs
may also impart an indirect anti-tumour effect through anti-
angiogenic activity.
Several preclinical studies have examined the anti-tumour
activity of inhibitors of EGFR and anti-angiogenic agents in
combination and have demonstrated at least additive, if not
synergistic, effects (Ciardiello et al, 2000; Jung et al, 2002; Herbst
et al, 2003). Previous experimental studies showed potential
beneficial anti-tumour effects when combining anti-angiogenic
agents with radiotherapy (RT) (Wachsberger et al, 2005; Nieder
et al, 2006), resulting in at least additive effects on tumour growth
delay despite different radiation schedules, drugs and doses and
combination regimens. Clinical research in this field is ongoing
but additional preclinical studies are needed to further evaluate
drug combinations, including the targeting of EGFR and VEGF
signalling pathways in association with RT.
Tumour vasculature is a key target in the treatment of solid
tumours, particularly in head and neck cancer (Le and Giaccia,
2003). In a recent study (Bozec et al, 2007), we investigated the
effects of combining anti-angiogenic treatment, EGFR targeting
and RT. We evaluated AZD2171, a highly potent, orally active,
VEGF signalling inhibitor, gefitinib, an EGFR tyrosine kinase
inhibitor, and RT. The anti-tumour efficacy of these treatments,
administered alone and in combination for 2 weeks, was assessed
in a VEGF-secreting human head and neck tumour cell line,
CAL33, that highly expresses EGFR, established as xenografts
(250mm
3) in nude mice. The median time to reach a tumour
volume of 1000mm
3 was significantly increased for AZD2171 or
gefitinib administered alone compared with the control. Greater
inhibition of tumour growth was seen with the combination
AZD2171þgefitinib compared with either drug alone, and the
triple combination compared with either AZD2171þgefitinib or
RT alone.
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sThe aim of this study was to examine the anti-tumour effects of
the clinically representative anti-angiogenic monoclonal antibody
bevacizumab combined with the anti-EGFR tyrosine kinase
inhibitor erlotinib and RT. To this end, we adopted an orthotopic
head and neck cancer xenograft model consisting in injecting
CAL33, a human head and neck cancer cell line, into the mouth
floor of nude mice. This model was used to enable examination of
the effects of treatment on the primary tumour itself and also, for a
more clinically relevant condition, on disease extension to the
lymph nodes in the neck. Molecular markers were also examined
according to the applied treatments. Ki67 expression was
considered as a relevant and classical parameter related to tumour
proliferation. The key VEGF receptor present on endothelial cells
is VEGFR2. In addition, the presence of VEGFR2 has been reported
on tumour cells themselves, particularly in head and neck cancer
(Neuchrist et al, 2001). For this reason, we analysed VEGFR2
expression both on endothelial cells and on tumour cells.
MATERIALS AND METHODS
Chemicals
Erlotinib was kindly provided by Roche (Neuilly sur Seine, France)
and bevacizumab by our institution’s pharmacy. Working solu-
tions were prepared as follows: erlotinib (7.5gl
 1) was suspended
in 0.9% NaCl and 0.01% Tween 80, and bevacizumab (750mgl
 1)
was diluted in 0.9% NaCl. For both drugs, the concentrations were
adjusted so as to include the daily dose in 0.2ml of drug
suspension. Dulbecco’s modified Eagle’s medium (DMEM),
penicillin, streptomycin and glutamine were purchased from
Whittaker (Verviers, Belgium). Fetal bovine serum (FBS) was
obtained from Dutscher (Brumath, France).
Cell line
CAL33, a cell line of human head and neck origin, was obtained in
our institution (Centre Antoine-Lacassagne). This cell line exhibits
high EGFR levels (33794±624fmol per mg protein; high-affinity
sites determined by ligand binding assay; Dassonville et al, 1993)
and produces VEGF (Cercina Onesto, CNRS-UMR6543, personal
communication).
The cell line was maintained as monolayer culture in DMEM
supplemented with 10% FBS v/v, 2mM glutamic acid, 50000Ul
 1
penicillin and 80mM streptomycin in a humidified incubator
(Sanyo, Japan) at 371C in an atmosphere containing 8% CO2.
Batches of 15 10
6 cells were frozen in FBS supplemented with 5%
dimethyl sulphoxide v/v in advance for injection into mice. Shortly
before injection, cells were thawed and suspended in Ringer
lactate.
Mice
Six-week-old female NMRI nude mice were purchased from
Janvier Laboratories (Le Genet sur Isle, France). They received,
as intra-muscular orthotopic xenograft in the mouth floor as
described by Myers et al (2002), an injection of 0.5 10
6 cells
suspended in 200ml of Ringer lactate (n¼10 per treatment
condition). There were five animals per cage with food and water
available ad libitum; animals were killed and tumours collected at
day 10 after cell injection by cervical disruption (as determined in
a preliminary experiment, the 12th day after tumour cells injection,
tumour development in the mouth floor prevented correct feeding
of the animals with consequent unethical suffering). As no signs of
suffering appeared during the experiment (submissive attitude,
weight loss, prostration, vocalisation), no animal had to be killed
before the end of the experiment. Animal experiments were
performed in accordance with the regulations of our institution’s
ethics commission and guidelines of the United Kingdom Co-
ordinating Committee on Cancer Research (Workman et al, 1998).
Treatment
Three days after cell injection, the mice were treated each week
with relevant vehicle (controls), erlotinib (50mgkg
 1, 5 days a
week, 0.2ml p.o.), bevacizumab (5mgkg
 1 per day, 5 days a week,
0.2ml i.p.) and irradiation (6Gy, 3 days a week every other day 2h
after drugs on tumour bed only) given alone or in combination;
when co-administered, erlotinib and bevacizumab were given
simultaneously (given the short duration of treatment   7 days  
five doses of each drug and four doses of irradiation were
delivered); the doses of erlotinib and bevacizumab were chosen
according to preliminary experiments (25, 50, 100 and 200mgkg
 1
p.o. for erlotinb and 5mgkg
 1 per day, 5 days a week, 0.2ml i.p.
for bevacizumab every day during 2 weeks), performed on tumour
of this same cell line xenografted in the flank of animals, so that
each drug given alone exerted only partial effects on tumour
growth.
Evaluation of drug effects
On the 10th day after cell injection, animals were killed and
weighed. Primary tumours were measured (tumour volume was
determined by the formula TV¼p/6 length width
2) and
weighed, and bilateral radical neck dissection was performed
(animals were killed by spinal cord dislocation and nodes and
tumours were subsequently removed surgically and fixed in
paraformaldehyde overnight). The effects of erlotinib, bevacizu-
mab and RT, alone or in combination, on tumour growth were
evaluated by measuring, for all groups, the mean tumour volume
(MTV). Combination ratios (CR), as described previously (Prewett
et al, 2002), were calculated from the mean tumour volumes of
treated and untreated tumours at the end of the treatment period
(day 10, after cell injection). This was carried out for control
(MTVcontrol), treatment a (MTVa), treatment b (MTVb), treat-
ment c (MTVc), treatment aþb (MTV aþb) and treatment
aþbþc (MTVaþbþc).
CR aþb¼MTVa MTVb/MTVaþb MTVcontrol
CR aþbþc¼MTVa MTVb MTVc/MTVaþbþc (MTVcontrol)
2
If CR41, there were supra-additive effects and if CRo1, infra-
additive ones. Strictly additive effects were observed if CR¼1.
The total number of pathologically positive lymph nodes, having
signs of inflammation either invaded or not, having a visible
diameter (greater than 1mm), were recorded after node chain
dissection after tumour removal.
Analysis of tumour markers
All analyses of tumour markers were performed on the primary
tumours, which were collected 10 days after tumour cell injection.
The expression of the microvessel marker VEGFR2 and of the
proliferation marker Ki67 was evaluated using immunohistochem-
istry (Cell Signalling Technology rabbit monoclonal antibody
55B11 and DAKO monoclonal antibody, ref. M7240 and MIB-1,
respectively). The analysis of VEGFR2 involved vessel loss and
reduction in vessel area, which were evaluated both at the tumour
centre and tumour periphery, and also a more diffuse labelling of
tumour cells; in this case, both the intensity (1, 2 or 3) of labelling
and the proportion of tumour cells were taken into account. The
analysis of Ki67 took into account the proportion of labelled cells;
labelling of each microscopic field was attributed to three labelling
groups: group 1 with 15–50% of labelled cell nuclei; group 2 with
50–70% of labelled cell nuclei; and group 3 with more than 70% of
labelled cell nuclei. For each treatment group, the relative
proportion of each of the three labelling groups (1, 2 or 3) was
pooled and represented as a histogram.
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sForty  10 magnification images of regions of high vascular
density within the tumour were analysed to quantify both tumour
angiogenesis and tumour cell diffuse labelling (VEGFR2). What-
ever the studied marker (Ki67 or VEGFR2), the final score was the
result of the examination of a maximum of 10, a minimum of 2 and
a mean of 5 fields per tumour, which, due to the small volume of
the tumour, allowed a thorough examination; 10 tumours were
investigated for each treatment group.
Statistical analyses
Comparison of primary tumour growth, node number, state of
invasion and the effects of treatment on VEGFR-2 and Ki67
between different treatment groups were evaluated using the non-
parametric ANOVA (Kruskal–Wallis test).
RESULTS
Effects of treatments on tumour growth
Treatments given alone had no significant impact on primary
tumour mass, with erlotinib and RT slightly decreasing tumour
growth (35 and 30% tumour mass reduction as compared to the
control, respectively, P40.05) (Figure 1). The combination of
erlotinib and bevacizumab induced a significant primary tumour
mass decrease (60%, P¼0.028 vs controls) and showed supra-
additive effects (CR¼2).
Finally, the triple combination bevacizumabþerlotinibþRT
gave the highest tumour growth inhibition (85%, Po0.0004 vs
controls; Po0.0001 vs RT; P¼0.02 vs bevacizumabþerlotinib).
The effects of this triple combination were supra-additive
(CR¼2.3).
Effects of bevacizumab, erlotinib, RT and their
combinations on pathologically positive lymph nodes
The effects of single treatments by erlotinib, bevacizumab or RT on
the number of nodes and the proportion of invaded nodes
paralleled their impact on primary tumour mass with a slight but
not significant decrease in the total node number and the
proportion of invaded nodes for erlotinib and RT, and a slight
but not significant enhancement of invaded nodes with bevacizu-
mab (Figure 2).
In contrast, and corroborating the observations on the primary
tumour mass, the combination erlotinibþbevacizumab totally
prevented node invasion (P¼0.03 vs controls). However, the drug
combination had no effect on the total number of pathologically
positive lymph nodes. In contrast, the bevacizu-
mabþerlotinibþRT triple combination produced a very signifi-
cant decrease in the total number of pathologically positive lymph
nodes (Po0.001 vs controls) although invaded nodes were still
present among these markedly reduced pathologically positive
lymph nodes.
Effects of bevacizumab, erlotinib, RT and their
combinations on proliferation markers (Ki67 labelling)
Neither erlotinib (small decrease) nor bevacizumab (small
increase) administered alone had a significant impact on tumour
cell proliferation (P40.05 vs controls) (Figure 3). In contrast, RT
application induced cell proliferation (P¼0.007 vs controls). This
RT-related effect on tumour cell proliferation was diminished by
the presence of erlotinibþbevacizumab to a level similar to the









































Figure 1 Primary tumour growth after 10 days of treatment with single
agents and combinations (10 mice per treatment group). Bars denote s.d.;
NS¼nonsignificant (P40.05); *Po0.05; **Po0.01; ***Po0.001. Values
above the columns concern comparisons with the controls; other values





























































Invaded node (N+R–) 
Figure 2 Impact of single agents and combinations on pathologically
positive lymph nodes (10 mice per treatment group). The only significant
differences were for node invasion status (bevacizumabþerlotinib vs
control, P¼0.03) and for total node number (bevacizu-
mabþerlotinibþRT vs control, Po0.001). An illustrative example of an
invaded node without capsular rupture (NþR ) is given.
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sEffects of bevacizumab, erlotinib, RT and their
combinations on tumour vessels (VEGFR2 labelling)
Bevacizumab given alone induced a decrease in endothelial cell
VEGFR2 labelling (Figure 4). Nevertheless, this change was not
significant as compared to controls; in contrast, RT induced a
strong ( 2) and very significant (Po0.001) increase in tumour
angiogenesis. Of note, this RT-related effect on tumour vessels was
no longer observed when RT was combined with erlotinib and
bevacizumab. The results of the examination of peripheral tumour
vessels were found to be superimposable with those of the central
part of the tumour (data not shown).
Effects of bevacizumab, erlotinib and their combination on
VEGFR2 labelling of tumour cells
All targeted treatments were found to diminish VEGFR2 expres-
sion on tumour cells (Figure 5). The combination erlotinibþ
bevacizumab led to a significant decrease as compared to controls.
Interestingly, a single application of RT alone also had a marked
impact on VEGFR2-labelled cells.
DISCUSSION
There are recent preclinical background (Bozec et al, 2006) and
early clinical trials (Caponigro et al, 2005; Meyerhardt et al, 2007)
that indicate that targeting both EGFR pathway and tumour
angiogenesis may be a useful strategy in the management of several
tumour pathologies. Head and neck cancer is particularly relevant
in this respect. As recently underlined by Forastiere and Burtness
(2007), there are compelling clinical data showing that head and
neck cancer is an ideal malignancy for EGFR inhibition either with
antibodies or small-molecule tyrosine kinase inhibitors. This is
especially evident for combinations between EGFR targeting drugs
and cytotoxic agents such as irradiation (Bonner et al, 2006; Harari
and Huang, 2006) or chemotherapy (Siu et al, 2007). This
background led us to undertake the present experimental study
on head and neck cancer xenograft considering the triple
association of EGFR targeting by erlotinib combined with the
anti-angiogenic agent bevacizumab and associated with irradiation.
Doses of individual agents were chosen to generate relatively
limited effects and thus allow detection of potential interactions.
This is for this reason that bevacizumab had no evident impact on
tumour growth per se and that erlotinib exhibited moderate anti-
tumour effects as a single drug (Figure 1). Interestingly, the
combination of the two drugs produced supra-additive effects on
the primary tumour mass with a combination ratio value at 2. We
recently made a similar observation when applying on CAL33 cells
growing as a classical xenograft the anti-angiogenic multi-target
tyrosine kinase inhibitor AZD2171 associated with the anti-EGFR
agent gefitinib (Bozec et al, 2007). One of the possible explanations
for the presently observed supra-additive anti-tumour activity may
lie in an optimal ‘vertical blockade’ of VEGF pathway not obtained
by either agent alone bearing in mind that EGFR targeting leads to
inhibition of VEGF tumour secretion (Byers and Heymach, 2007).
As recently underlined by O’Reilly (2006), there is a preclinical
rationale to combine anti-angiogenic agents with radiation. The
association between anti-EGFR therapy and radiation is based on
consistent preclinical data confirmed at the clinical level,





















Group 1 Ki67 labelling   Group 2 Ki67 labelling   Group 3 Ki67 labelling  
200 µm 200 µm 200 µm
Figure 3 Impact of the different treatments on Ki67 proliferation marker (10 mice per treatment group). The proportion of primary tumours with
labelling less than 50% is shown in white (group 1), between 50 and 70% in grey (group 2) and more than 70% in black (group 3); NS¼nonsignificant
(P40.05); *Po0.05; **Po0.01; ***Po0.001. Values above the columns concern comparisons with the controls; other values concern comparisons
between two following columns. An illustrative example of each labelling group is given.
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sstudy, the combination bevacizumabþerlotinib was considered as
a whole when associated with irradiation. This triple combination
was found to be supra-additive for cytotoxic activity on the
primary tumour (CR¼2.3; Figure 1). We observed both irradia-
tion-related induction of tumour proliferation (Figure 3) and an
increase in tumour angiogenesis following irradiation (Figure 4).
This phenomenon may be due, at least in part, to the post-
radiation induction of EGFR signalling in irradiated cells
previously reported by others (Schmidt-Ullrich et al, 1996) and
us (Bozec et al, 2005). It is known that VEGF secretion is under the
control, at least in part, of EGFR signalling (Goldman et al,
1993). Interestingly, these radiation-related stimulations of
both tumour cell proliferation and tumour angiogenesis
were markedly diminished by the presence of the drug
combination, with the EGFR-targeting drug probably playing a
role in the attenuation of radiation-induced tumour proliferation.
In addition, bevacizumab strengthens these latter effects by
counterbalancing the local production of VEGF by the tumours.
The present study confirms the presence of VEGFR2 expression

































Weak VEGFR2 labelling of  tumour cells  Strong VEGFR2 labelling of tumour cells 
100 µm 
Figure 5 Impact of the different treatments on VEGFR2 expression on tumour cells (10 mice per treatment group). NS¼nonsignificant (P40.05);
* Po0.05; **Po0.01; ***Po0.001. Indications above the columns concern statistical comparisons with the controls; other indications concern statistical































Sagittal section of a vessel 
VEGFR2 labelling at the centre of  a tumour  
100 µm
Figure 4 Impact of the different treatments on the number of tumour vessels labelled by the anti-VEGFR2 antibody measured at the centre.
NS¼nonsignificant (P40.05); ***Po0.001. Indications above the columns concern statistical comparisons with the controls; other indications concern
statistical comparisons between two following columns. An illustrative example of VEGFR2 labelling of the vessels is given.
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sbefore by Neuchrist et al (2001). Taken together, it seems likely
that two overlapping systems are involved in the tumorigenicity
and tumour angiogenesis with autocrine/paracrine loops using
VEGF and VEGFR2. Clearly, the present data indicate that the
combination of two targeted drugs with RT is particularly well
suited for interrupting this vicious circle and has thus a marked
preferential impact on tumour cells carrying VEGFR2. The
presence of expression of VEGFR2 in head and neck cancers
could be indicative of cases potentially sensitive to this innovative
combination.
This study was also specifically designed to examine the impact
of treatment not only on the primary tumour itself but also on the
local metastatic invasion in nodes, thus creating a condition of
clinical relevance. This was made possible by the adoption of a
head and neck orthotopic model (Myers et al, 2002). This aspect is
particularly relevant for head and neck cancer, as this type of
cancer has a loco-regional evolution with frequent neck involve-
ment, which is the most important parameter for prognosis
(Pentenero et al, 2005). Of importance, the present data
demonstrate a differential effect of the respective treatments on
node involvement, lending additional clinical significance to the
observations obtained from the examination of the primary
tumours. Thus, the combination erlotinibþbevacizumab
confirmed the supra-additive anti-tumour effects by markedly
reducing pathologically positive lymph nodes whereas the activity
of single drugs at this level was less evident, particularly in the case
of bevacizumab (Figure 2). Of clinical interest was the fact that the
therapeutic condition leading to fewer macroscopically evident
nodes was the triple combination erlotinibþbevacizumabþ
irradiation.
In total, this study provides another strong rationale for a
combination between irradiation and EGFR pathway targeting
plus anti-angiogenic treatment (Bozec et al, 2007). The conclusion
drawn from the specific experimental conditions with a head
and neck cancer orthotopic xenograft model strengthens the
clinical applicability of the presently investigated treatment
strategy not only for the management of head and neck cancer
but also for other major tumour pathologies such as non-small-cell
lung cancer (Maione et al, 2006), colorectal cancer (Arsene et al,
2006) and glioblastoma multiforme (Newton, 2007) in which
EGFR targeting and anti-angiogenic treatments are particularly
active.
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